Loading...
XSHE
300534
Market cap553mUSD
Oct 09, Last price  
12.52CNY
1D
2.45%
1Q
66.93%
Jan 2017
-31.32%
IPO
102.87%
Name

Gansu Longshenrongfa Pharmaceutical Industry Co Ltd

Chart & performance

D1W1MN
XSHE:300534 chart
P/E
86.41
P/S
4.33
EPS
0.14
Div yield, %
0.33%
Shrs. gr., 5y
-0.01%
Rev. gr., 5y
24.99%
Revenues
878m
-15.52%
133,365,959212,676,485274,889,691301,575,287277,360,874269,681,015269,587,022203,165,802239,003,312254,899,756287,813,045287,813,044413,246,804799,681,4281,080,050,0281,039,067,295877,853,450
Net income
44m
+70.32%
13,897,07225,255,87440,912,09060,424,35260,677,16947,252,34317,112,16912,277,84512,777,5071,831,1310-9,106,15825,826,45738,785,12761,647,66125,804,60243,950,793
CFO
-6m
L
10,163,23235,624,00035,917,46539,007,99430,601,50313,135,424010,232,91328,208,54343,500,88051,134,88411,426,98596,526,292170,144,339-5,737,006
Dividend
May 22, 20260.02 CNY/sh

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

Gansu Longshenrongfa Pharmaceutical Industry Co.,Ltd operates as a pharmaceutical enterprise, focusing on the research, development, manufacturing, and commercialization of traditional Chinese medicines, health supplements, and active pharmaceutical ingredients (APIs). Its extensive product line includes therapeutic remedies such as Yuanhu Analgesic dropping pills, Qiwei Wenyang capsules, Maxing cough capsules, Shuxinning tablets, Panax notoginseng pills, Anti-inflammatory and gallbladder tablets, Children's Qingfei cough tablets, Pediatric Qinggan tablets, Suanzaoren oil dropping pills, Xiaoshuan Tongluo tablets, Xiaoyanlidan tablets, Compound Danshen tablets, Astragalus Angelica capsules, and berberine tannin films. Beyond its core manufacturing, the company is actively involved in the cultivation, procurement, processing, and distribution of Chinese medicinal raw materials. Its operations further encompass project investment and management, alongside the import, sale, logistics, and export of pharmaceutical goods. Established in 2002, Gansu Longshenrongfa Pharmaceutical Industry Co.,Ltd is headquartered in Lanzhou, China.

Key people

Rong Xiao
Chief Financial Officer · since 2025
Yuehong Song
General Manager, Chief Engineer, Director · since 2024
Wenliang Chen
Deputy General Manager · since 2024
Bo Sun
Deputy General Manager · since 2024
Qinhui Yuan
Deputy General Manager, Secretary of the Board, Director · since 2017
Rui Fu
Director · since 2024
Yonghong Kang
Chairman of the Board · since 2025
Kaicai Zhu
Director · since 2025
Independent Director · since 2025
Independent Director · since 2020
Zhen Luo
Independent Director · since 2020
Ye Wu
Independent Director · since 2024
IPO date
Sep 13, 2016
Employees
Domiciled in
CN
Incorporated in
CN

Valuation

Title
CNY in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFYFYFY
2025‑122024‑122023‑122023‑002022‑122022‑002021‑122020‑122019‑122018‑122017‑122016‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT